Paid Clinical Trials in Nashville, TN
As of July 2026, 1,354 paid clinical trials are recruiting in Nashville, Tennessee. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Nashville offers studies at sites including Vanderbilt University Medical Center for conditions such as Breast Cancer, Colorectal Cancer, Advanced Solid Tumor, Ovarian Cancer. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Nashville
Filter results
Newly added in Nashville
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
45 clinical trials
·Clear filters·↓ Download CSVA Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
DESTINY-PANTUMOUR04
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
About research studies in Nashville
Nashville has approximately 1,354 recruiting research studies across a wide range of therapeutic areas. Tennessee is home to Vanderbilt University Medical Center and St. Jude Children's Research Hospital — world leaders in pediatric oncology and personalized medicine.
Top Research Study Locations in Nashville
Researchers run research studies in Nashville, TN at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Vanderbilt University Medical Center | Parkinson Disease, Colorectal Cancer, ARDS | 369 |
| SCRI Oncology Partners | Breast Cancer, Colorectal Cancer, Advanced Solid Tumor | 127 |
| Vanderbilt University/Ingram Cancer Center | Head and Neck Squamous Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | 86 |
| Sarah Cannon Research Institute | Advanced Solid Tumor, Advanced Solid Tumors, Colorectal Cancer | 62 |
| Vanderbilt University | Breast Cancer, Cardiac Failure, Graft Rejection | 55 |
| Tennessee Oncology | Breast Cancer, Carcinoma, Non-Small-Cell Lung, Chronic Lymphocytic Leukemia | 48 |
| Vanderbilt-Ingram Cancer Center | Breast Cancer, Colorectal Cancer, Endometrial Cancer | 39 |
| The Children's Hospital at TriStar Centennial | Malignant Solid Neoplasm, Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia | 28 |
| Monroe Carell Jr. Children's Hospital at Vanderbilt | Hypertension, Acute Kidney Injury, Acute Myeloid Leukemia | 13 |
| Tennessee Oncology, PLLC | Advanced Solid Tumor, Breast Cancer, Advanced Breast Cancer | 13 |
| TriStar Centennial Medical Center | Acute Lower Limb Arterial Occlusion, Acute Myeloid Leukemia (AML), Aortic Stenosis | 12 |
| Vanderbilt Breast Center at One Hundred Oaks | Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Solid Neoplasm, Advanced Malignant Solid Neoplasm | 12 |
| Tennessee Valley Healthcare System Nashville Campus, Nashville, TN | Cardiovascular Disease, Acute Kidney Injury (AKI), Aging | 10 |
| Ascension Saint Thomas | Coronary Artery Disease, Mitral Regurgitation, Acute or Chronic Coronary Artery Disease | 9 |
| Sarah Cannon Research Institute Oncology Partners | Advanced Solid Tumors, Advanced Cancer, Advanced NRAS-Mutant Melanoma | 9 |
| GSK Investigational Site | Neoplasms, Irritable Bowel Syndrome, Multiple Myeloma | 8 |
| Tennessee Retina, PC | Geographic Atrophy, Neovascular Age-Related Macular Degeneration (nAMD), AMD | 8 |
| Vanderbilt Eye Institute | Geographic Atrophy (GA), Macular Edema Secondary to Inflammation, Age - Related Macular Degeneration (AMD) | 8 |
| Henry-Joyce Cancer Clinic | Colorectal Neoplasms, Breast Cancer, Colonic Diseases | 7 |
| Sarah Cannon Research Institute (SCRI) Oncology Partners | Advanced Solid Tumor, Metastatic Solid Tumor, Ovarian Cancer | 7 |
| Autonomic Dysfunction Center/ Vanderbilt University Medical Center | Autonomic Failure, Multiple System Atrophy, Pure Autonomic Failure | 6 |
| Centennial Medical Center | Cardiovascular Diseases, Coronary Artery Disease, Heart Failure | 6 |
| Sarah Cannon Research Institute - Pharmacy | Gastroesophageal Junction Adenocarcinoma, Advanced Cancer, Advanced Colorectal Cancer (Part 1) | 6 |
| Urology Associates, P.C. | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Cancer of the Prostate, Hormone Sensitive Prostate Cancer | 6 |
| Vanderbilt Ingram Cancer Center | AL Amyloidosis, Adamantinomatous Craniopharyngioma, Advanced or Metastatic Colorectal Cancer | 6 |
Active & Upcoming Studies in Nashville (2026)
Recruiting trials in Nashville grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (562 active studies)
- A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · Bristol-Myers Squibb
- Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) · Phase 1 · Vanderbilt-Ingram Cancer Center
Cardiovascular (86 active studies)
Neurology & pain (60 active studies)
- Individual vs Co-Treatment in Acute Stroke Rehabilitation and Evaluation · Vanderbilt University Medical Center
- Cholinergic Deep Brain Stimulation for Alzheimer's Disease · Vanderbilt University Medical Center
Diabetes & metabolic (52 active studies)
- A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes · Phase 3 · Eli Lilly and Company
- A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) · Phase 3 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Eye & vision (21 active studies)
- A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated · Phase 1, Phase 2 · Boehringer Ingelheim
- Clinical Evaluation of Lifitegrast Ophthalmic Solution 5.0% in Dry Eye Disease Using In Vivo Confocal Microscopy · Phase 4 · Toyos Clinic
Mental health & behavior (14 active studies)
- Cognitive Enhancement in Recurrent Depression (The COG-D-R Study) · Vanderbilt University Medical Center
- GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · Vanderbilt University Medical Center
Pediatric (9 active studies)
- Neonatal Platelet Transfusion Threshold Trial · NICHD Neonatal Research Network
- Project PAIR: Parent-implemented Articulation Intervention With Recast · Vanderbilt University
Vaccines (8 active studies)
- Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS · Phase 2 · Vanderbilt University Medical Center
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) · Phase 2 · Vanderbilt University Medical Center
HIV / STI (8 active studies)
- GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · Vanderbilt University Medical Center
- A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
Common conditions studied in Nashville
- Breast Cancer (42 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Colorectal Cancer (31 active studies). Colorectal cancer trials explore novel chemotherapy combinations, targeted agents, and immunotherapy for microsatellite-instability-high tumors.
- Advanced Solid Tumor (30 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Ovarian Cancer (26 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Advanced Solid Tumors (22 active studies). Recruiting Advanced Solid Tumors studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Endometrial Cancer (22 active studies). Recruiting Endometrial Cancer studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Nashville
- Vanderbilt University Medical Center
- AstraZeneca
- National Cancer Institute (NCI)
- Vanderbilt-Ingram Cancer Center
- Merck Sharp & Dohme LLC
Local regulations and guidelines
Clinical trials in Tennessee are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Tennessee research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Nashville. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Nashville
Hipa.ai aggregates every recruiting study in Nashville from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Nashville?
There are approximately 1,354 recruiting clinical trials in Nashville, Tennessee listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Nashville pay participants?
Most recruiting trials in Nashville compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Nashville?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Nashville?
The most common conditions under active study in Nashville include Breast Cancer (42), Colorectal Cancer (31), Advanced Solid Tumor (30), Ovarian Cancer (26), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Nashville?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Nashville on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Nashville?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Nashville?
Recruiting research sites in Nashville include Vanderbilt University Medical Center, SCRI Oncology Partners, Vanderbilt University/Ingram Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Nashville right now?
The largest active categories in Nashville are Cancer & tumors (562), Cardiovascular (86), Neurology & pain (60). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.